<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:department>Liverpool School of Tropical Medicine</gtr:department><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3931EE52-E837-4B71-9F2C-46E766B3570D"><gtr:id>3931EE52-E837-4B71-9F2C-46E766B3570D</gtr:id><gtr:firstName>Jimmy</gtr:firstName><gtr:surname>Whitworth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B47CFAF4-CABB-442D-A110-7B41D652A6E3"><gtr:id>B47CFAF4-CABB-442D-A110-7B41D652A6E3</gtr:id><gtr:firstName>Alex</gtr:firstName><gtr:surname>Coutinho</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C02A0294-8267-4C18-AA4D-6186D308971D"><gtr:id>C02A0294-8267-4C18-AA4D-6186D308971D</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Lalloo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100035"><gtr:id>3663DCB6-CA63-4846-A03A-4C59C1E2BE59</gtr:id><gtr:title>Primary prevention of invasive cryptococcal disease using fluconazole prophylaxis in HIV infected Ugandans</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100035</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1019969</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public dissemination in UK</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>B81C41CA-819D-49B3-AD43-CD96A8D3C2B3</gtr:id><gtr:impact>Press release with MRC in UK

none</gtr:impact><gtr:outcomeId>EEA67D47AAD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Public dissemination in Uganda</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>30602A6D-DC3C-454F-A7C0-8A486BDACAC9</gtr:id><gtr:impact>Media briefing

Nil</gtr:impact><gtr:outcomeId>7F4B08C365B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Feedback to participants</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>DB8B4D17-5338-4BEA-A9B7-FCB447323631</gtr:id><gtr:impact>Discussion of trial results with participants and HIV positive patients

Engagement of participants</gtr:impact><gtr:outcomeId>AEC69C97CE5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MOH in Uganda</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>C4D4845D-325A-4C44-A988-B50007CDEF89</gtr:id><gtr:impact>Presentation of results to Uganda Ministry of Health

Discussions about changing policy</gtr:impact><gtr:outcomeId>22A0F9FC900</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MOH engagment</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>B2ED60A9-672B-4CE1-AE6C-468EE9B6779B</gtr:id><gtr:impact>Presentation of evidence to MOH. Ongoing discussions about whether this should be rolled out in Uganda</gtr:impact><gtr:outcomeId>7D3A7701F3F</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Fluconazole prophylaxis</gtr:description><gtr:id>542A1392-E279-48ED-8A9B-192772ACFCF0</gtr:id><gtr:impact>Reduction in incidence</gtr:impact><gtr:outcomeId>TB8zboAdCGh</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>CRYPTOPRO</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6C096E6F-0A55-4E3C-BE66-1BA0DBE85F56</gtr:id><gtr:title>Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9656df631da2183c1fe52a54c1392f46"><gtr:id>9656df631da2183c1fe52a54c1392f46</gtr:id><gtr:otherNames>Wakeham K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>01AC4359676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>602EEAC3-980F-4D4C-A702-29D1CC48D5AE</gtr:id><gtr:title>Use of nail and oral pigmentation to determine ART eligibility among HIV-infected Ugandan adults.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a812e4f1abe545f9b5ed7c881ce39f76"><gtr:id>a812e4f1abe545f9b5ed7c881ce39f76</gtr:id><gtr:otherNames>Namakoola I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>mPJXwCvFN5P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48BA5C11-3DD4-4878-B0EA-C6C36B935ABB</gtr:id><gtr:title>Symptom burden in HIV-infected adults at time of HIV diagnosis in rural Uganda.</gtr:title><gtr:parentPublicationTitle>Journal of palliative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9656df631da2183c1fe52a54c1392f46"><gtr:id>9656df631da2183c1fe52a54c1392f46</gtr:id><gtr:otherNames>Wakeham K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1557-7740</gtr:issn><gtr:outcomeId>ZGPXhMsfUDq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE0C854F-DFD0-44CD-A26D-04DEC866E0FC</gtr:id><gtr:title>Development of Severe Anemia and Changes in Hemoglobin in a Cohort of HIV-Infected Ugandan Adults Receiving Zidovudine-, Stavudine-, and Tenofovir-Containing Antiretroviral Regimens.</gtr:title><gtr:parentPublicationTitle>Journal of the International Association of Providers of AIDS Care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2325-9574</gtr:issn><gtr:outcomeId>56b0ded21558e6.70803800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F841BB48-A6C7-4922-8FD6-F1862DDE7513</gtr:id><gtr:title>Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>qK3LeoVaSDa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A15F053-0011-4C34-8ECF-842E42046B62</gtr:id><gtr:title>Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1461034a32f8f6f0aacd600c262622c"><gtr:id>a1461034a32f8f6f0aacd600c262622c</gtr:id><gtr:otherNames>Parkes-Ratanshi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>otMRhGRRnPb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4B8291D-33DD-40BD-B097-3CBB17E6216B</gtr:id><gtr:title>Treatment of cryptococcal meningitis in resource limited settings.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7d8df257e748e69522231f52f1a1bc7"><gtr:id>a7d8df257e748e69522231f52f1a1bc7</gtr:id><gtr:otherNames>Sloan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>9FF40EBB4EB</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100035</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>